

## Special Issue

# Tumour Angiogenesis and Anti-Angiogenic Therapy

### Message from the Guest Editor

The traditional perspective on tumour vascularization holds that tumours derive their blood supply from the surrounding normal stroma. However, research has shown that alternative mechanisms, including intussusceptive angiogenesis, vasculogenic mimicry, vessel co-option, and vasculogenesis, also contribute to tumour vascularization. Various immunohistochemistry (IHC) studies on tumour biopsies identified tumour blood vessel markers (e.g., CD31, CD34 on endothelial cells and Smooth Muscle Actin (SMA), Desmin on pericytes). This Special Issue highlights recent advancements in identifying and characterizing tumour blood vessel biomarkers, as well as anti-angiogenic therapies designed for clinical applications to target vascularization across various tumour types. The goal is to encourage new research in tumour angiogenesis, fostering the development of therapeutic drugs aimed at targeting tumour vascularization thereby preventing tumour progression and metastasis of tumours.

---

### Guest Editor

Dr. Krishna Priya Syama

Environmental Health Sciences and Research Bureau (EHSRB), Healthy Environments and Consumer Safety Branch (HECS), Health Canada, Ottawa, ON K1A 0R6, Canada

---

### Deadline for manuscript submissions

31 January 2026



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/244159](https://mdpi.com/si/244159)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).